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ABSTRACT
Glutamate Dysregulation in a TauP301L Mouse Model of Alzheimer’s Disease
Holly C. Hunsberger
Individuals at risk for developing Alzheimer’s disease (AD) often exhibit neuronal
network hyperexcitability, particularly in the CA3 region of the hippocampus, in the years
preceding AD diagnosis, suggesting that aberrant network activity might contribute to the
pathogenesis of AD. Recently, the microtubule-binding protein tau has been implicated in this
hyperexcitability. Removal of tau in AD models overexpressing amyloid-β (Aβ) or non-AD
models of epilepsy decreases hyperexcitability and normalizes the excitation/inhibition
imbalance. The exact mechanism by which tau produces hyperexcitability remains to be
determined, but recent work suggests tau may mediate glutamatergic signaling. Glutamate is the
primary excitatory neurotransmitter in the central nervous system and changes in glutamatergic
neurotransmission affect the overall activity of neuronal networks. Although beneficial at low
levels, high concentrations of extracellular (EC) glutamate can lead to cell death through
excessive activation of glutamate receptors, a process referred to as excitotoxicity and linked to
several neurodegenerative disorders, including AD. Here, we used a tau mouse model of AD
(rTg(TauP301L)4510) to examine whether mutant P301L tau expression alters synaptic
glutamate regulation in the dentate gyrus (DG), CA3 and CA1 regions of the hippocampus. To
examine glutamate regulation in vivo, we used an amperometry coupled to ceramic-based
microelectrode arrays (MEAs), which allows for measurement of tonic glutamate levels,
potassium-evoked glutamate release, and glutamate clearance from the synapse. P301L tau
expression did not affect tonic extracellular glutamate levels or clearance from the synapse in
any region examined. Similarly, amplitudes of potassium-evoked glutamate release were similar
between controls and TauP301L mice in the DG and CA1. However, memory-impaired
TauP301L mice exhibited a 7-fold increase in glutamate release in the CA3 region of the
hippocampus, and spatial reference memory errors correlated with potassium-evoked glutamate
release in the CA3. These data suggest a possible novel mechanism, increased presynaptic
glutamate release, by which tau may mediate hyperexcitability.
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Glutamate Dysregulation in TauP301L Mice
Alzheimer’s disease (AD) affects approximately 5.4 million Americans and is often
characterized by progressive memory loss, decline in cognitive skills, and adverse behavioral
changes (Thies & Bleiler, 2013). Biologically, Alzheimer’s disease is characterized by an
abundance of extracellular amyloid plaques, comprised of aggregates of beta-amyloid (Aβ), and
intracellular neurofibrillary tangles containing hyperphosphorylated tau protein (Serrano-Pozo,
Frosch, Masliah, & Hyman, 2011). The third major feature of AD is an alteration of neuronal
connections, eventually leading to massive neuron loss throughout the brain. Recent work
suggests AD-related pathology begins in particularly vulnerable regions of the brain, including
the entorhinal cortex and hippocampus, part of the brain’s memory network, before spreading to
other cells along the same neural network (de Calignon et al., 2012; Liu et al., 2012; Nath et al.,
2012).
Effective regulation of activity in these neural networks is essential. Because both
increases and decreases in stimulation can impair neuronal function and survival, neural network
dysfunction could contribute directly to the neurodegenerative process (Palop, Chin, & Mucke,
2006). An early feature in aging, before AD pathology, is the hyperactivity of the memory
network, specifically in the CA3 region of the hippocampus. In studies using functional magnetic
resonance imaging (fMRI), elevated hippocampal activation is observed in individuals at risk for
AD, including cognitively normal carriers of the ApoE4 allele, a known genetic risk factor for
AD (Dennis et al., 2010; Filippini et al., 2009; Trivedi et al., 2008), pre-symptomatic carriers of
genetic mutations in familial AD (Quiroz et al., 2010), patients with mild cognitive impairment
(MCI) (Dickerson et al., 2005; Hamalainen et al., 2007), and asymptomatic and minimally
impaired older individuals with amyloid deposition (Sperling et al., 2009). Furthermore,
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longitudinal fMRI assessments of ApoE4 allele carriers indicate that hippocampal overactivation
correlates with declines in memory (Bookheimer et al., 2000).
Hippocampal hyperactivity was once believed to serve a compensatory function for
deteriorating circuitry by recruiting extra neural resources (Bondi, Houston, Eyler, & Brown,
2005; Grady et al., 2003; Ward & Frackowiak, 2003). However, more recent studies show
excess activation may contribute directly to memory impairment and AD-related pathology and
could represent a therapeutic target. Circumstantial human evidence supports this view; patients
with temporal lobe epilepsy, who exhibit substantially elevated neuronal activity, develop
amyloid plaques as early as 30 years of age (Mackenzie & Miller, 1994). Similarly, seizures and
epileptiform activity are associated with an early age at onset of cognitive decline and precede or
coincide with diagnosis of aMCI or AD (Vossel et al., 2013).
The relation between hyperactivity and memory impairments is more than correlational;
treatments targeting excess CA3 activation dose-dependently improved memory performance in
memory-impaired aged rats; these same doses had no effect in young rats without memory
impairments, suggesting dampening of hippocampal hyperactivity, not merely a global cognitive
enhancement, was responsible for the memory improvement in aged rats (Koh, Haberman, Foti,
McCown, & Gallagher, 2010). Furthermore, a reduction in aberrant neural network activity
reversed the synaptic and cognitive deficits observed in an Aβ mouse model of AD (Sanchez et
al., 2012). Evidence for the adverse consequences of hyperexcitability has also been shown in
humans; reducing hippocampal CA3 activation in an amnestic MCI group improved memory
performance (Bakker et al., 2012). Together, these studies suggest targeting excess hippocampal
activity may have therapeutic potential.
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The increased activity of the CA3 could be due to an increase in excitatory glutamatergic
signaling or a decrease in inhibitory GABA-ergic signaling, or both. For the purpose of the
current project, we will focus on alterations in the glutamatergic system. Glutamate, the major
excitatory neurotransmitter, is responsible for many of the brain’s functions including cognition
and memory (Curtis, Phillis, & Watkins, 1960; Sheldon & Robinson, 2007). Glutamate is
believed to contribute to hippocampal-dependent learning and memory through long-term
potentiation (LTP) (Bliss & Collingridge, 1993), a long-lasting strengthening in signal
transmission between two neurons that results from their synchronous stimulation (Bliss &
Gardner-Medwin, 1973; Bliss & Lomo, 1973). Although beneficial at low levels, high
concentrations of extracellular (EC) glutamate can lead to cell death through excessive activation
of glutamate receptors, a process referred to as excitotoxicity (Olney, Price, Samson, &
Labruyere, 1986). Excitotoxicity is linked to several neurodegenerative disorders, including
Alzheimer’s disease (Hardingham & Bading, 2010b), and occurs when uncontrolled glutamate
release surpasses the capacity of astrocyte clearance mechanisms, leading to an excess of EC
glutamate. The following are believed to be the steps fundamental for excitotoxicity: First,
excess glutamate accumulates in the synapse, which activates presynaptic ionotropic
(Dingledine, 1983; Watkins & Evans, 1981) and metabotropic receptors (Aleppo et al., 1992;
Sacaan & Schoepp, 1992), leading to further release of glutamate. Glutamate then binds AMPA
receptors, leading to depolarization sufficient for magnesium (Mg2+) to be expelled from NMDA
channels. NMDA channels open, permitting large amounts of calcium (Ca2+) to enter. Although
this is a physiological process necessary for learning and memory, excess EC glutamate leads to
prolonged exposure to glutamate and an excess of intracellular Ca2+ (Choi, 1992; Choi, Koh, &
Peters, 1988; Eimerl & Schramm, 1994). Thus, the normally tightly regulated Ca2+ levels exceed
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a threshold that leads to activation of several enzymes, including phospholipases, endonucleases,
and proteases, such as calpain, that mediate cell death (Annunziato, Cataldi, Pignataro, Secondo,
& Molinaro, 2007). Most studies have examined the link between aberrant neuronal activity and
Aβ (Hsia et al., 1999; Mucke et al., 2000; Shankar et al., 2007). The role of tau in mediating
neuronal hyperexcitability is less clear but is supported by several recent studies showing that
reductions in tau substantially reduce hyperexcitability in Aβ mouse models, induced seizure
models, and models of epilepsy (DeVos et al., 2013; Holth et al., 2013; Ittner et al., 2010;
Roberson et al., 2007; Roberson et al., 2011). Further examination of the role of tau is warranted.
Similarly, though many studies have implicated glutamate in the pathophysiology of AD, most
have done so through indirect measures, such as increased signaling of downstream pathways
related to excitotoxicity (Hong et al., 2012; Saito, Elce, Hamos, & Nixon, 1993; Zhang et al.,
2010) or in cell culture models (Jamsa et al., 2006; Petroni, Tsai, Mondal, & George, 2011).
Thus, it is essential that an increase in EC glutamate be confirmed in the pathophysiology of AD
and the relation to tau pathology identified.
The Excitatory Life of Glutamate
Because of glutamate’s role in LTP and findings of glutamate receptors on almost all
neurons (Danbolt, 2001), glutamate is one of the most intensely researched neurotransmitters.
This interest is heightened by findings of imbalances in glutamate signaling in many disease
processes (see (Sheldon & Robinson, 2007) for review), including stress (see (Popoli, Yan,
McEwen, & Sanacora, 2012) for review), stroke (Harvey et al., 2011), traumatic brain injury
(Schmidt & Grady, 1993), and several neurodegenerative diseases (Sheldon & Robinson, 2007),
including AD (Scott, Pow, Tannenberg, & Dodd, 2002). The next sections detail the life of
glutamate, from its synthesis, to its packaging into vesicles and release into the synapse, its
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activity once in the synapse, its uptake into astrocytes, and its eventual breakdown. The
subsequent sections describe how these steps are altered and can lead to an excess of glutamate
signaling, with an emphasis on changes documented in AD. Other diseases are used to highlight
alterations not yet examined in AD but that may represent novel mechanistic links between AD
and glutamate excitotoxicity.
Glutamate synthesis. The synthesis of glutamate, a nonessential amino acid, begins with
glucose via the tricarboxylic acid cycle (TCA) (Krebs & Johnson, 1937). Glucose, located in the
astrocyte, then forms citrate, and subsequently synthesis of alpha-ketoglutarate. Glutamate is
then metabolized after the conversion of alpha-ketoglutarate by aspartate aminotransferase or
glutamate dehydrogenase (Waagepetersen, Qu, Sonnewald, Shimamoto, & Schousboe, 2005).
Glutamate can also be synthesized from glutamine. In the glutamate-glutamine cycle,
glutamate is synaptically released and taken up by surrounding astrocytes, where it is converted
to glutamine, a non-neuroexcitatory amino acid, and transferred back to neurons for conversion
to glutamate (Norenberg & Martinez-Hernandez, 1979). The flow of glutamate from neurons to
astrocytes is approximately equal to the flow of glutamine from astrocytes to neurons (Rae et al.,
2003).
Glutamate release. Glutamate release is mediated by both vesicular and nonvesicular
processes (Bollmann, Sakmann, & Borst, 2000). For vesicular release, glutamate moves into the
lumen of the presynaptic vesicles via vesicular glutamate transporters (VGLUTs) (Sudhof,
2004). VGLUTs are located in the presynaptic membrane and package glutamate into vesicles
before exocytosis into the synaptic cleft (Takamori, Rhee, Rosenmund, & Jahn, 2000).
Following presynaptic neuronal depolarization, calcium (Ca2+) channels open, permitting the
influx of Ca2+ and triggering the fusion of VGLUTs with the membrane, resulting in the
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exocytosis of glutamate into the synapse (see (Benarroch, 2010) for review). The three isoforms
of VGLUT are VGLUT1, VGLUT2, and VGLUT3. VGLUT1 and VGLUT2 are specific to
glutamatergic neurons (Massie, Schallier, Vermoesen, Arckens, & Michotte, 2010) whereas
VGLUT3 is found in cholinergic, serotoninergic, and GABA-ergic neurons (Gras et al., 2002).
Though VGLUTs were once believed to be found in both presynaptic neurons and astrocytes,
more recent evidence suggests that VGLUTs are not expressed in astrocytes, at least not in the
mouse brain (D. Li et al., 2013).
Glutamate can also be released into the synapse via a nonvesicular route that involves the
cystine/glutamate antiporter (Xc-) (Baker, Xi, Shen, Swanson, & Kalivas, 2002). This antiporter
is a plasma membrane-bound, sodium-independent, anionic amino acid transporter (Bannai,
1986) located on astrocytes that functions by exchanging one molecule of extracellular cystine
for one molecule of intracellular glutamate (Bannai, 1986).
Glutamate receptors. Once in the extracellular space, glutamate can bind to ionotropic
(iGluR) or metabotropic (mGluR) receptors (see (Kew & Kemp, 2005; Schoepp, 2001) for
review). The iGLuRs include: N-methyl-D-aspartate (NMDA), α-amino-3-hydroxy-5methylisoxazole-4-propionic acid (AMPA), and kainic acid (KA) (Nakanishi, 1992). NMDA
receptors (NMDARs) are ligand-gated ion channels that constitute a majority of glutamate
receptors in the mammalian brain and differ from AMPA and KA receptors in three ways. First,
NMDARs are unique in that they require two obligatory co-agonists (Johnson & Ascher, 1987;
Kleckner & Dingledine, 1988). Both glutamate and glycine binding sites must be occupied for
NMDAR activation to occur (Johnson & Ascher, 1987; Kleckner & Dingledine, 1988). Second,
NMDARs are not only ligand-gated, but also voltage-gated (Nowak, Bregestovski, Ascher,
Herbet, & Prochiantz, 1984). At resting potential, the channel is blocked by Mg2+ even if the co-
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agonists are bound to the receptor. Activation of AMPA- or KA- receptors, which depolarizes
the neuron, is required to relieve the Mg2+ blockade. Because NMDARs require concomitant
presynaptic (release of glutamate) and postsynaptic (depolarization) activities, NMDARs detect
the coincidence of two events and are sometimes referred to as coincidence detectors. In
addition, NMDARs have a higher permeability to Ca2+ than AMPA- or KA- receptors
(Dingledine, 1983; MacDermott, Mayer, Westbrook, Smith, & Barker, 1986). The increased
influx of Ca2+ triggers secondary messenger systems leading to the establishment of LTP, a
process believed to underlie learning and memory (Bliss & Collingridge, 1993). However,
overactivation of NMDARs leads to an excess of intracellular Ca2+, which initiates a series of
events leading to cell death (Choi, 1987; Choi et al., 1988; Choi, Maulucci-Gedde, & Kriegstein,
1987).
NMDARs have seven subunits (NR1, NR2A-D, and NR3A-B) with NR1 and NR3
binding to glycine (Nilsson, Duan, Mo-Boquist, Benedikz, & Sundstrom, 2007) and NR2
binding to glutamate (Kutsuwada et al., 1992). NMDARs are heteromeric complexes containing
NR1 subunits and a combination of NR2 and/or NR3 subunits. Because NR3A is restricted to
expression during development (Al-Hallaq et al., 2002) and NR3B is restricted to brain regions
not involved in early stages of AD [i.e., the somatic motor neurons of the brainstem and spinal
cord (Fukaya, Hayashi, & Watanabe, 2005)], focus in the next section will be given to NR1/NR2
complexes. Likewise, NR1/NR2 complexes play an important role in learning and memory (Cao
et al., 2007), as well as excitotoxicity (von Engelhardt et al., 2007), and are abundantly located in
the hippocampus, one of the first regions affected in AD (Braak & Braak, 1998; Du et al., 2004;
van de Pol et al., 2007).
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AMPA and KA are agonized by AMPA and kainate, respectively and are more
permeable to sodium (Na+) and potassium (K+) than Ca2+ (Burnashev et al., 1992; van de Pol et
al., 2007). AMPA and KA receptors have an immediate response upon binding of glutamate, and
the influx of Na+ causes depolarization, leading to the removal of the Mg2+ block of NMDARs
(Chittajallu et al., 1996; Tang, Dichter, & Morad, 1989). AMPA receptors are composed of a
four-subunit family (GluR1-4) (Hollmann, Hartley, & Heinemann, 1991; Keinanen et al., 1990).
GluR1, 3, and 4 allow Ca2+ permeability, whereas the GluR2 removes this permeability
(Hollmann, Hartley, & Heinemann, 1991). KA receptors have subunits ranging from GLuR5-7,
also referred to as GluK5-7 or KA1-2 (Bettler et al., 1990; Bettler et al., 1992; Egebjerg, Bettler,
Hermans-Borgmeyer, & Heinemann, 1991; Herb et al., 1992; Werner, Voigt, Keinanen, Wisden,
& Seeburg, 1991). Of the two, AMPARs are the more commonly studied in relation to AD.
The mGLuRs are G-protein coupled and subdivided into three groups: Group I, II, and III
(Masu, Tanabe, Tsuchida, Shigemoto, & Nakanishi, 1991). Of the Group I mGLuRs, mGluR1s
are located pre- and post-synaptically, while mGluR5s are located post-synaptically and on glia.
Both play a role in synaptic plasticity, though mGluR1s are associated with both LTP and LTD,
whereas mGluR5s are associated only with LTD (Charpak, Gahwiler, Do, & Knopfel, 1990;
Desai & Conn, 1991; Desai, Smith, & Conn, 1992). Though both Group I mGluR subtypes are
found in the hippocampus, the subtypes are distributed differentially in the cornu ammonis (CA)
1 and 3 pyramidal cells of the hippocampus; both mGluR1 and mGluR5 cells are found in CA3
cells, whereas CA1 cells only express mGluR5s (Lujan, Nusser, Roberts, Shigemoto, &
Somogyi, 1996; Shigemoto et al., 1993).
Group II mGLuRs (mGLuR2 and 3) are located primarily at the pre-synapse of glutamate
neurons, where they act as a negative feedback system, though mGluR3s are also located post-
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synaptically and on glial cells. These receptors, particularly the mGluR2s, act to inhibit
glutamate release upon stimulation (Yokoi et al., 1996). Because spillover of glutamate is
necessary for activation of these receptors (Scanziani, Salin, Vogt, Malenka, & Nicoll, 1997),
they appear to serve a protective role. Until recently, mGluR3 function was thought to be
associated with GABA expression only (Ghose et al., 1997). However, in 2003 it was shown that
activation of astrocystic mGluR3s resulted in increased expression of glutamate transporters
(GLAST and GLT-1), while knockout of mGluR3s resulted in a down regulation of GLAST and
GLT-1 expression (Lyon, Kew, Corti, Harrison, & Burnet, 2008). Together, these studies suggest
mGluR3s may regulate EC glutamate via changes in transporter expression (Aronica et al.,
2003). Furthermore, in 2005 mGluR3s were found to be required for LTD in the hippocampus
(Poschel, Wroblewska, Heinemann, & Manahan-Vaughan, 2005).
Group III mGLuRs (mGLuR 4, 6, 7, and 8), located on both the pre and post synapse,
primarily act to negatively modulate glutamate transmission (Kinoshita, Shigemoto, Ohishi, van
der Putten, & Mizuno, 1998; Semyanov & Kullmann, 2000). mGLuRs 4 and 7 negatively
modulate glutamate transmission in the hippocampus (Semyanov & Kullmann, 2000) while
mGluRs 4 and 8 are located presynaptically in the CA3 region of the hippocampus and decrease
glutamate release following activation (Sansig et al., 2001; Semyanov & Kullmann, 2000).
mGLuRs 7, however, have a lower affinity for glutamate than other mGLuRs, suggesting that
these receptors may only become active if glutamate levels are high and may serve as a check for
glutamate excitotoxicity (Sansig et al., 2001). mGLuRs 6 are only found in the retina and act to
inhibit cell hyperpolarization (Tian & Kammermeier, 2006). These receptors are directly
involved in glutamate transmission in the visual sensory system.
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Glutamate uptake. For proper neurological functioning, it is essential that glutamate
levels in the extracellular space remain low. Because there are no enzymes to degrade glutamate,
the only way to end glutamate signaling is through its uptake via receptors known as excitatory
amino acid transporters (EAATs) (Danbolt, 2001). The EAATs are ATP-dependent transporters,
meaning they require energy in the form of ATP to remove glutamate from the synapse. This is
important because a depletion of oxygen, such as during a stroke (Lo, Dalkara, & Moskowitz,
2003), can lead to a decrease in ATP, resulting in a decrease in glutamate uptake and an excess
of EC glutamate.
There are five known EAATs (Danbolt, 2001). Only EAAT1 and EAAT2, also referred
to as GLAST and GLT-1 respectively, are expressed in rodent brains (Storck, Schulte, Hofmann,
& Stoffel, 1992). GLAST and GLT-1 are primarily responsible for glutamate uptake and are
located on astrocytes (Lehre, Davanger, & Danbolt, 1997; Lehre, Levy, Ottersen, StormMathisen, & Danbolt, 1995). EAAT3 is present on postsynaptic neurons in the in the CA1 region
of the hippocampus and the granular layer of the dentate gyrus, and its uptake of glutamate is
sodium dependent (Crino et al., 2002). While GLAST and GLT-1 are found only in the brain,
EAAT3 can also be found in the intestines, kidney, liver, and heart (Kanai & Hediger, 1992).
CNS expression of EAAT3 is relatively low compared to that of GLT and GLAST (Haugeto et
al., 1996). EAAT4 is expressed primarily in the cerebellum purkinje cells, while EAAT5 is
found in retinal neurons and is involved in visual processing (Arriza, Eliasof, Kavanaugh, &
Amara, 1997).
Glutamate degradation. Following astrocytic uptake, glutamate is converted into
glutamine via the glutamine synthetase pathway (Norenberg & Martinez-Hernandez, 1979).
Astrocytes dispose of glutamate by converting it to glutamine (Martinez-Hernandez, Bell, &
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Norenberg, 1977) or alpha-ketoglutarate (McKenna, Sonnewald, Huang, Stevenson, & Zielke,
1996) through amination processes. Glutamine is then released into the extracellular space where
it is taken into presynaptic terminals via sodium coupled neutral amino acid transporters (SNAT3
and SN1) (Boulland et al., 2002). Conversion of glutamate to glutamine before release into the
extracellular space prevents glutamate–induced neuronal depolarization (Danbolt, 2001;
McKenna & Sonnewald, 2005)). Following presynaptic uptake, glutamine is converted into
glutamate as described in the glutamate synthesis section (Ramaharobandro, Borg, Mandel, &
Mark, 1982).
Glutamate’s Role in the Pathophysiology of Disease
Although glutamate is essential for learning and memory, excess glutamate in the
synapse can cause overexcitation of postsynaptic receptors, eventually leading to neuronal death
through apoptosis (Olney & de Gubareff, 1978). This process is termed excitotoxicity and is
observed in many disease processes (Olney, 1969). The following section describes ways in
which EC glutamate can accumulate to reach pathological levels. Though focus will be given to
glutamate alterations observed in AD, glutamate dysregulation in other diseases will be used to
highlight potentially novel, as yet unexamined, mechanisms underlying excitotoxicity pathology
in AD.
Alterations in glutamate synthesis. The glutamate/glutamine pathway provides a path
to rapidly recycle glutamate, but alterations in glutamate synthesis can lead to changes in
glutamate levels (Lieth, LaNoue, Antonetti, & Ratz, 2000). For example, diabetes reduces
glutamine synthetase (GS), an enzyme that converts glutamate to glutamine, leading to glutamate
accumulation (Lieth et al., 2000). Individuals with schizophrenia also exhibit decreased levels of
GS and elevated glutamine synthetase-like protein (GSLP) and glutamate dehydrogenase
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enzymes (GDH) (Burbaeva et al., 2003). It is not yet known why GSLP or GDH are elevated or
if these findings suggest elevated or decreased glutamate levels, as evidence suggests both hyperand hypo- function of glutamate in the etiology of schizophrenia (see (Krystal et al., 1999) for
review).
Decreased GS levels have also been found in biopsies of human AD brains, and
decreased levels of GDH have been found in other neurodegenerative disorders (Plaitakis,
Flessas, Natsiou, & Shashidharan, 1993; Robinson, 2000). The possible role of GS in AD
etiology is still unclear, but blockade of GS prevents memory consolidation (Gibbs et al., 1996).
Likewise, GS levels decline with age (Hensley et al., 1994; Smith et al., 1991). Given that age is
the greatest risk factor for AD, age-related decreases in GS might be one of many ways in which
aging increases the risk for AD.
Alterations in glutamate release. Another way in which glutamate can reach
pathological levels in the extracellular space includes increases in the packaging of glutamate
into vesicles using VGLUTs. VGLUT protein expression levels correspond to the strength of
presynaptic glutamate levels (Massie et al., 2010) and increased VGLUT expression causes
excitotoxic neurodegeneration (Daniels, Miller, & DiAntonio, 2011). In a rodent model of
Parkinson’s disease, another neurodegenerative disease associated with excitotoxicity (Surmeier,
2007), VGLUT1 expression is increased (Massie et al., 2010). Although alterations in VGLUT
expression have not been reported in the AD literature to date, preliminary data from the Reed
lab (Figure 1) shows increased VGLUT1 expression in mice expressing human tau carrying the
proline to leucine mutation at the 301st amino acid (rTg(TauP301L)4510, herein called
TauP301L). These mice exhibit neurofibrillary tangles, neurodegeneration and progressive
memory decline (Ramsden et al., 2005; Santacruz et al., 2005) and are commonly used to study
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the role of tau pathology in AD. These are also the mice used in the current study and will be
described in greater detail below.
The cystine-glutamate antiporter (Xc-) may also be responsible for excitotoxic effects.
Increased expression of the Xc- system leads to an increase in glutamate release (Pampliega et al.,
2011) and is observed in several diseases associated with neurodegeneration and glutamate
excitotoxicity. For example, Xc- expression is increased in multiple sclerosis (Pampliega et al.,
2011), hypoxic neuronal injury (Fogal, Li, Lobner, McCullough, & Hewett, 2007), Parkinson’s
disease (Massie et al., 2008), gliomas (Savaskan et al., 2008), and around plaques in AD mouse
models (Qin et al., 2006).
Alterations in glutamate receptors. As EC glutamate levels increase, differential
activation of NMDARs occurs. At low levels, glutamate primarily activates synaptic NMDARs
(see (Kew & Kemp, 2005; Schoepp, 2001) for review), which predominantly contain the NR2A
subunit (Anson, Chen, Wyllie, Colquhoun, & Schoepfer, 1998). Synaptic NMDARs mediate
neuronal survival and resistance to trauma via their anti-apoptotic and antioxidant effects
(Hardingham, 2006; Hetman & Kharebava, 2006; Leveille et al., 2010). In contrast,
extrasynaptic NMDARs, located on the spine neck, dendritic shaft, or soma (Petralia, Sans,
Wang, & Wenthold, 2005), are activated only by high glutamate concentrations (Hardingham,
2006) or glutamate released from astrocytes (Bezzi et al., 2004). Activation of extrasynaptic
NMDARs (predominately containing the NR2B subunit) is associated with neurotoxicity by
stimulating cell death pathways (Hardingham, Fukunaga, & Bading, 2002; Thomas, Grandy,
Gerhardt, & Glaser, 2009). The pathways triggered by extrasynaptic NMDARs are often in direct
opposition to those triggered by synaptic NMDARs (Ivanov et al., 2006). One particularly
relevant example includes the differential effects on CREB (cyclic-AMP response element
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binding protein), a transcription factor essential for the conversion of short-term memory to longterm memory (Brightwell, Gallagher, & Colombo, 2004; Deisseroth, Bito, & Tsien, 1996; Impey
et al., 1998). Synaptic NMDARs activate CREB (Hardingham et al., 2002), whereas
extrasynaptic NMDARs inactivate CREB, and this inactivation dominates over the effects of
synaptic NMDAR activation (Hardingham & Bading, 2010a; Hardingham et al., 2002; Papadia
et al., 2008). The differential effects on CREB suggest one way in which excess EC glutamate
may contribute to memory deficits.
Increased activation of extrasynaptic NMDARs may also mediate tau pathology in AD.
Increased activation of NR2B-containing receptors induces tau phosphorylation, while blockade
of NR2B receptors prevents this phosphorylation (Allyson, Dontigny, Auberson, Cyr, &
Massicotte, 2010). Likewise, blockade of extrasynaptic NR2B receptors abolishes tau-mediated
cytotoxicity in a cell culture system (Amadoro et al., 2006). Memantine, used to treat AD,
preferentially blocks extrasynaptic NMDARs at low doses, while sparing normal synaptic
activity (Xia, Chen, Zhang, & Lipton, 2010). Memantine treatment reduces tau phosphorylation
(Song, Rauw, Baker, & Kar, 2008) and excitotoxicity (Okamoto et al., 2009) while increasing
memory functioning (Parsons, Stoffler, & Danysz, 2007). We hypothesize that in our TauP301L
mouse model, a self-propagating, feed-forward loop of toxicity might exist in which the
increased expression of VGLUT1 (Figure 1) leads to an increase in EC glutamate and increased
activation of extrasynaptic NMDARs. This increased activation is predicted to then exacerbate
tau phosphorylation.
mGLuRs may also receptors mediate excitotoxicity. For example, activation of Group I
mGluRs (predominantly mGluR5) activate protein kinase C (PKC), which enhances NMDARmediated neuronal toxicity (Bruno et al., 1995) by creating longer lasting calcium channel
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openings (Wagey, Hu, Pelech, Raymond, & Krieger, 2001). Blocking of group I mGluRs
reduces neurological deficits produced by glutamate release in traumatic brain injury (Gong,
Delahunty, Hamm, & Lyeth, 1995). mGluR1 knockout mice, however, exhibit learning and LTP
deficits (Gil-Sanz, Delgado-Garcia, Fairen, & Gruart, 2008), suggesting some activity at these
sites is needed for normal cognitive functioning.
Both Group II and III act primarily through negative feedback systems such that when
activated further glutamate release is suppressed, but their role excitotoxicity is controversial.
While some believe group II mGluRs to be neuroprotective when activated (Movsesyan &
Faden, 2006), others have shown that group II activation does not prevent neuronal
excitotoxicity (Behrens et al., 1999).
Alterations in glutamate uptake. Decreases in glutamate transporters can also lead to
increased EC glutamate levels. EAATs are significant in that they control and limit glutamate
spillover between adjacent synapses (Diamond, 2001). EAAT abnormalities may arise through
various mechanisms, including alterations in trafficking, phosphorylation or cleavage of EAATs,
alterations in mRNA splicing, increases in EAAT turnover, or reductions in transport capacity
(see (Maragakis & Rothstein, 2004) for review). One mechanism particularly relevant to
neurodegenerative diseases includes inhibition of EAATs in response to oxidative damage
(Trotti, Rolfs, Danbolt, Brown, & Hediger, 1999), a common problem in many
neurodegenerative diseases (Uttara, Singh, Zamboni, & Mahajan, 2009).
Decreases in EAATs have been reported in an Aβ mouse model of AD (Masliah et al.,
2000), as well as in mice expressing mutant tau in astrocytes (Forman et al., 2005). Interestingly,
the decrease in EAATs occurred prior to tau accumulation (Forman et al., 2005), suggesting
alterations in EC glutamate may precede tau pathology. With normal aging, transporter
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expression declines, but this decrease is exacerbated in AD patients (Zoia et al., 2004).
Decreases in EAATs are found in the midfrontal cortex of AD patients (Li, Mallory, Alford,
Tanaka, & Masliah, 1997) but not in the cingulate and inferior temporal gyri (Beckstrom et al.,
1999). Likewise, individuals with amyotrophic lateral sclerosis (ALS), another
neurodegenerative disorder, also exhibit decreases in glutamate transporters and increases in EC
glutamate (Rothstein et al., 1996).
To Be Resolved.
AD is part of a group of neurodegenerative diseases collectively known as tauopathies in
which tau, a microtubule-associated protein responsible for stabilizing microtubules, becomes
abnormally hyperphosphorylated. Once hyperphosphorylated, tau no longer binds to tubulin nor
promotes microtubule assembly, and mislocalizes from axons to the somato-dendritic
compartment, where it accumulates to form insoluble tangles (see (Iqbal, Liu, Gong, & GrundkeIqbal, 2010) for review). Because tau hyperphosphorylation precedes tangle formation,
identifying and therapeutically targeting factors that increase tau hyperphosphorylation are of
considerable interest. Previous work (e.g., (Allyson et al., 2010; Hardingham et al., 2002;
Thomas et al., 2009)) suggests alterations in glutamate signaling represent one such target.
Determining whether tau can disrupt glutamate signaling, in the absence of Aβ pathology,
represents a first step towards this ultimate goal. To determine the role of tau in glutamate
dysregulation, we used TauP301L mice. Though these mice eventually exhibit age-dependent
tangles, cognitive decline, and neuron loss (Ramsden et al., 2005; Santacruz et al., 2005), we
examined glutamate dysregulation at a time point prior to such changes because
electrophysiological hyperexcitability (e.g., an increased action potential firing rate) is prominent
in these mice prior to tangle deposition or neuronal death (Crimins, Rocher, & Luebke, 2012).
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In Alzheimer’s disease, the hippocampus is one of the first regions affected (Braak &
Braak, 1998; Du et al., 2004; Szapiro et al., 2002; van de Pol et al., 2007). This increased
vulnerability is related in part to the high concentration of glutamate receptors (Greenamyre &
Young, 1989) that mediate communication of the trisynaptic circuit of the hippocampus. This
circuit is composed of three distinct subregions (Figure 2), the dentate gyrus (DG),
cornuammonis 3 (CA3) and cornuammonis 1 (CA1). Although the pathway works as a circuit,
each subregion has unique characteristics, including differences in synaptic connectivity, surface
expression of glutamate receptors, gene expression profiles, and levels of glutamate release and
clearance following KCl-evoked release (Gegelashvili, Danbolt, & Schousboe, 1997; Greene,
Borges, & Dingledine, 2009; N. R. Wilson et al., 2005). Below, a rationale for examining each of
these three regions separately is made.
The entorhinal cortex (EC), which is the first region affected in AD, projects to the DG.
In patients with AD, interruption of the granule cells from the entorhinal cortex to the DG
impairs learning and memory (Gomez-Isla et al., 1996; West & Slomianka, 1998). Second,
though Aβ deposits in the CA1 region of the hippocampus during Braak stage 1 and 2 of AD,
cognitive deficits are not detectable until Aβ deposits in the DG during stage 3 (Thal et al.,
2000). Third, the DG may be more vulnerable to tau pathology because it contains less NFTresistant nitric oxide synthases (NOS) neurons relative to other regions of the hippocampus
(Rebeck, Marzloff, & Hyman, 1993).
The CA3 region may be of interest because hyperactivity in this region is observed in
memory-impaired, aged rats (Wilson, Ikonen, Gallagher, Eichenbaum, & Tanila, 2005), as well
as MCI patients (Bakker et al., 2012; Yassa et al., 2010) and those at genetic risk for AD (Dennis
et al., 2010; Filippini et al., 2009; Trivedi et al., 2008). This hyperactivity is partially due to a
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loss of inhibitory innervation from cholinergic cells in the basal forebrain (Chouinard, Gallagher,
Yasuda, Wolfe, & McKinney, 1995; Sugaya et al., 1998), which releases the CA3 recurrent,
autoassociation fibers from inhibition, leading to greater activity (Leutgeb, Leutgeb, Treves,
Moser, & Moser, 2004). Similarly, loss of EC to DG innervation results in a loss of inhibitory
input to CA3, resulting in increased CA3 activity (Bragin, Jando, Nadasdy, van Landeghem, &
Buzsaki, 1995).
Finally, the CA1 also exhibits tau pathology (Fukutani et al., 1995), and though the DG
seems to be most sensitive to aging (Small, Chawla, Buonocore, Rapp, & Barnes, 2004), the
CA1 region shows a greater loss of neurons related to AD than any other region (West, Kawas,
Martin, & Troncoso, 2000). Thus, glutamate regulation in all three regions of the trisynaptic loop
was examined.
To study glutamate dysregulation in the DG, CA3, and CA1, we employed a novel
technique, in vivo amperometry coupled to enzyme-based microelectrode arrays (MEAs).
Previous studies employing the use of microdialysis experienced spatial and temporal limitations
that restricted the ability to sample dynamic changes in glutamate near the synapse (Hillered,
Vespa, & Hovda, 2005; Obrenovitch, Urenjak, Zilkha, & Jay, 2000)). Damage caused by the
large sample area (1–4 mm in length) limited the detection of neuronal release (Borland, Shi,
Yang, & Michael, 2005; Jaquins-Gerstl & Michael, 2009), and the low temporal resolution (1–20
min) was inadequate to measure the fast dynamics of glutamate uptake and clearance (Diamond,
2005). MEAs allow for such measures due to their high temporal resolution (10 Hz), low limit of
detection (<0.5 μM), and high spatial resolution, to selectively measure extracellular glutamate
close to synapses (Burmeister & Gerhardt, 2001; Burmeister et al., 2002). Another benefit of
MEAs over other ex vivo methods is the ability to study brain regions in vivo without disrupting
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their extrinsic and intrinsic connections, a particularly important consideration when examining
the complex neural networks of the hippocampus.
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Introduction
Alzheimer’s disease (AD) affects approximately 5.4 million Americans and is often
characterized by progressive memory loss, decline in cognitive skills, and adverse behavioral
changes (Thies & Bleiler, 2013). Pathologically, AD is characterized by accumulation of neuritic
Aβ plaques and abnormally phosphorylated tau leading to neurofibrillary tangles (Serrano-Pozo
et al., 2011). The third major feature in AD is the alteration of neuronal connections, eventually
leading to massive neuron loss throughout the brain. Neuropathology begins in the entorhinal
cortex and then extends to the hippocampus, before spreading to the associated areas of the
cortex (de Calignon et al., 2012; Liu et al., 2012; Nath et al., 2012).
Individuals at risk for developing AD often exhibit neuronal network hyperexcitability in
the years preceding AD diagnosis, suggesting that aberrant network activity might contribute to
the pathogenesis of AD. In studies using functional magnetic resonance imaging (fMRI),
elevated hippocampal activation is observed in individuals at risk for AD, including cognitively
normal carriers of the ApoE4 allele (Dennis et al., 2010; Filippini et al., 2009; Trivedi et al.,
2008), pre-symptomatic carriers of genetic mutations in familial AD (Quiroz et al., 2010),
patients with mild cognitive impairment (MCI) (Dickerson et al., 2005; Hamalainen et al., 2007),
and asymptomatic and minimally impaired older individuals with amyloid deposition (Sperling
et al., 2009). The CA3 region of the hippocampus is particularly prone to hyperexcitability (I. A.
Wilson et al., 2005). Although, hippocampal activity was thought to be compensatory by
recruiting extra neuronal resources (Bondi et al., 2005; Grady et al., 2003; Ward & Frackowiak,
2003), more recent studies show excess activation may contribute directly to memory
impairment and AD-related pathology and could represent a therapeutic target (Bakker et al.,
2012).
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Recent work suggests tau may mediate hyperexcitability. Genetic removal of tau
decreases seizure activity in an Aβ mouse model of AD (Roberson et al., 2011). Furthermore, in
this same mouse model, reducing endogenous tau ameliorated excitotoxicity and rescued
cognitive dysfunction, without altering Aβ levels (Roberson et al., 2007), suggesting tau, not Aβ,
was mediating excitotoxicity. Deletion of tau in mouse and drosophila models of epilepsy also
reduces hyperexcitability, as well as seizure frequency and duration (Daniels et al., 2011). The
exact mechanism for these changes remains to be determined, but recent work suggests tau may
alter glutamate neurotransmission (Roberson et al., 2007; Roberson et al., 2011; Timmer et al.,
2014).
Glutamate, the major excitatory neurotransmitter is responsible for many of the brain’s
functions, including long-term potentiation (LTP), and learning and memory (Bliss &
Collingridge, 1993). Although beneficial at low levels, high concentrations of extracellular (EC)
glutamate can lead to cell death through excessive activation of glutamate receptors, a process
referred to as excitotoxicity (Olney et al., 1986). Excitotoxicity is linked to several
neurodegenerative disorders, including AD (Hardingham & Bading, 2010b), and occurs when
uncontrolled glutamate release surpasses the capacity of astrocyte clearance mechanisms, leading
to an excess of EC glutamate. Though many studies have implicated glutamate in the
pathophysiology of AD, most have done so through indirect measures, such as increased
signaling of downstream pathways related to excitotoxicity (Hong et al., 2012; Saito et al., 1993;
Zhang et al., 2010) or in cell culture models (Jamsa et al., 2006; Petroni et al., 2011). In vivo
measurement of glutamate regulation in AD mouse models has been limited.
To determine the role of tau in glutamate dysregulation, the current study used TauP301L
mice. These mice exhibit age-dependent tangles, cognitive decline, and neuron loss (Ramsden et
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al., 2005; Santacruz et al., 2005). However, we sought to examine the effects of P301L tau on
glutamate dysregulation before neuron loss occurs (Hoover et al., 2010). TauWT animals were
used to control for the overexpression of human tau. Prior to glutamate testing, mice were
memory tested using the hippocampal-dependent Barnes maze (BM) task to ensure memory
impairments at the age tested. In vivo glutamate dysregulation was measured in the DG, CA3,
and CA1 subregions of the hippocampus, areas rich in glutamate receptors (Nimchinsky,
Yasuda, Oertner, & Svoboda, 2004; Pettit & Augustine, 2000), using a technologically
innovative technique, amperometry coupled to ceramic-based microelectrode arrays (MEAs).
Unlike previous studies using microdialysis, MEAs selectively measure extracellular glutamate
at 10 Hz enabling us to more precisely examine tonic glutamate levels, potassium chloride
(KCl)-evoked glutamate release, and glutamate clearance (Burmeister & Gerhardt, 2001;
Burmeister et al., 2002). Another benefit of MEAs over other ex vivo methods is the ability to
study brain regions in vivo without disrupting their extrinsic and intrinsic connections, a
particularly important consideration when examining the complex connections of the
hippocampus. Because all procedures were done within the same animal, we were able to relate
changes in glutamatergic signaling with behavioral changes.
Methods
Subjects. Creation of TauP301L mice has been described extensively in the past (Hoover
et al., 2010; Ramsden et al., 2005; Santacruz et al., 2005). Briefly, regulatable transgenic mice
expressing human four-repeat tau lacking the N-terminal sequences (4R0N) with a P301L
mutation were created by crossing a responder and activator line. Responder mice (FVB/N
background strain) heterozygous for the TRE-TauP301L transgene were bred with heterozygous
activator mice (129S6 background strain) that express the tet-off tetracycline transactivator (tTA)
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reading frame placed downstream of Ca2+/calmodulin kinase II (CaMKII) promoter elements
(Santacruz et al., 2005). The four genotypes of animals generated are described by the following
nomenclature, TauP301L/CKtTA, and include what we refer to as TauP301L mice (+/+) and
Controls (-/+, +/-, -/-). In the current study we used the (-/+) control because no behavioral
differences among the 3 Control groups has been reported, and human tau is not expressed in any
of the Controls (Hoover et al., 2010; Ramsden et al., 2005; Santacruz et al., 2005), yet the -/+
allowed us to control for the expression of tTA (Mayford et al., 1996). TauWT were generated in
the same way as TauP301L mice and have been shown to express wild-type 4R0N human tau at
concentrations equivalent to P301L human tau in TauP301L mice (Hoover et al., 2010). To
control for differences in copy number, which can affect transgene expression (Kong et al.,
2009), mice were littermate-matched, and litter served as the statistical unit.
The CaMKII promoter was used to restrict TauP301L protein expression to the forebrain
(Santacruz et al., 2005), which contains the brain regions most severely affected in AD (Auld,
Kornecook, Bastianetto, & Quirion, 2002), while the tet-off system allowed for regulatable
expression of the tau protein. In the tet-off system, the tTA protein binds to TRE in the absence
of doxycycline, allowing transcription and protein expression to occur (Liu, Wang, Brenner,
Paton, & Kasparov, 2008), whereas in the presence of doxycycline, the tTA protein cannot bind
to TRE, allowing tau expression to be suppressed. To suppress tau expression during brain
development, 40 ppm doxycycline hyclate (DOX) was administered (Figure 3) via water bottles
to breeder dams for three weeks prior to mating and to all experimental mice from birth until
1.85 months ± 1.5 weeks of age. Tau was expressed from two to seven months of age, with
behavioral testing at 4.93 months ± 1.28 weeks and glutamate testing at 7.01 months ± 3.29
weeks.
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Twenty-eight mice (7 Controls, 12 TauWT, 9 TauP301L) of an FVB/129S6 background
strain were group housed with free access to food and water in a temperature and humiditycontrolled colony room with a 12:12 light/dark cycle. Bodyweights did not differ among the
groups (Figure 6A). All experimental procedures were approved by the West Virginia University
Animal Care and Use Committee.
Barnes Maze. The Barnes maze consists of a circular white platform (122 cm), 108 cm
above the ground, with 40 holes (5 cm), one with a hidden escape box. Acquisition training was
performed as described previously with slight modification (McAfoose, Koerner, & Baune,
2009; McLay, Freeman, & Zadina, 1998). For the two days preceding acquisition trials, the mice
were habituated to the maze. The first day mice were placed under an opaque beaker, with lights
on and allowed to enter the escape box for 5 min. The next day the mouse was gently guided to
the escape box and allowed to remain in the escape box for 2 min. Each mouse completed two
trials each day with approximately 20-25 min between trials.
For acquisition training, on days 3-7, mice were placed under a transparent, plastic beaker
in the center of the platform, with lights on and four fans evenly placed around the maze. After
10 sec, the beaker was raised, and the mouse was free to find the escape box. The trials ended 30
sec after the mouse entered the escape box. If the mouse did not enter the escape box during the
3 min trial, the experimenter gently guided the mouse into the escape box and covered the hole
for 30 sec. Mice received 3 trials per day with 20-25 min between trials. The maze was cleaned
with 70% ethanol, rotated clockwise after every trial to avoid intra-maze odor or visual cues,
though the escape box remained in the same place relative to extra-maze cues. Total acquisition
errors were recorded.
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The first of two probe trials, in which the escape box was removed, took place 24 hr after
the last acquisition trial. The second probe trial took place one week following the first probe
trial. Probe trials lasted 90 sec. Latency to reach the target hole and number of errors made were
recorded. To further evaluate search strategy as previously described (Devan, Stouffer, Petri,
McDonald, & Olds, 2003), the probe trial was divided into three 30 sec epochs.
Enzyme-based microelectrode arrays. Ceramic-based MEAs were used to examine
glutamate dysregulation and were purchased from Quanteon, L.L.C. (Nicholasville, KY). The
array consisted of a ceramic-based multisite microelectrode with 4 platinum recording sites
(Burmeister & Gerhardt, 2001) (Figure 4A). These sites were arranged in dual pairs to allow
interfering agents to be detected and removed from the analyte signal (Burmeister & Gerhardt,
2001). Coating of the microelectrodes has been described previously (Hinzman et al., 2010).
Briefly, the recording sites were covered with glutamate-oxidase (GluOx) to oxidize glutamate to
alpha-ketoglutarate and hydrogen peroxide (H202), the reporter molecule (Burmeister &
Gerhardt, 2001). An inactive protein matrix covered the other pair of recording sites (sentinel
sites). Small molecules, like H202, could diffuse through the mPD exclusion layer and were
detected by both the sentinel and reporter sites. The background current from the sentinel sites
was then subtracted from the recording sites to produce a selective measure of extracellular
glutamate. A reference electrode Ag/AgCl was implanted into a remote site from the recording
area so as to decrease noise and instability (Burmeister & Gerhardt, 2001).
Calibration. Calibrations were conducted on the MEAs to ensure specificity prior to use
in mice and to create a standard curve for the conversion of current to glutamate concentration
(Figure 4B). Using the FAST-16 mkII system (Quanteon), a constant potential of + 0.7 V versus
an Ag/AgCl reference was applied to the MEA to oxidize the reporter molecule. The resulting
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current was amplified by the FAST 16 mkII system. The MEA tip was submerged in 40 mL of a
0.05 M phosphate-buffered saline (PBS) maintained at 37°C. A standard curve was produced by
adding successive aliquots of 20 μL glutamate to achieve concentrations of 20, 40, and 60 μM.
The increase in current (nA) produced by oxidation was used to calculate the calibration slope to
a known concentration of glutamate (Burmeister, et al., 2002). To determine selectivity for
glutamate, ascorbic acid (250 μM), dopamine (2 μM), and 8.8 H2O2 (8.8 μM) was added to
solution (Hinzman, Thomas, Quintero, Gerhardt, & Lifshitz, 2012). To determine the limit of
detection, the smallest concentration of glutamate that can be measured by the device, the slope
of the standard curve was used, as well as the linearity of glutamate response (R2) (Hinzman et
al., 2012). We also examined MEA performance after in vivo recordings. As previously reported,
post-implantation calibration demonstrated that the parameters were not different when
compared to pre-implantation (Hinzman et al., 2010). Both GluOX recording sites (pre- vs. postimplantation), reported as means (n=1 electrode): limit of detection (.54 μM vs. 2.26 μM), Rsquared (.99 vs. .99), and slope (.002 pA/μM vs. .002 pA/μM).
MEA/Micropipette Assembly. For intracranial drug deliveries, a glass micropipette with
an inner diameter tip of 10-15 μm (Quanteon) was attached to the MEA. The micropipette was
centered between the dorsal and ventral platinum recording pairs and positioned 80-100 μm
away from the MEA. Location of the micropipette to the MEA was verified post-surgery to
ensure the pipette did not move. The micropipette was back-filled with sterile-filtered isotonic
KCl solution (70 mM KCl, 79 mM NaCl, 2.5 mM CaCl2, pH 7.4) or glutamate solution (200 μM
glutamate, pH 7.4). The micropipette was attached to a Picospritzer III (Parker-Hannifin,
Cleveland, OH) and set to consistently deliver volumes of 50-100 nL. Pressure was applied from
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2 - 20 psi for .30-2.5 sec. Volume displacement was monitored with the use of a
stereomicroscope fitted with a reticule (Friedemann & Gerhardt, 1992).
In vivo Anesthetized Recording. Mice were anesthetized with isoflurane (1-4%
inhalation; continuous) and placed into a stereotaxic device (David Kopf Instruments, Tujunga,
CA, USA). Isoflurane was used because other anesthesias have been shown to alter resting
glutamate levels (Mattinson et al., 2011). Though initial reports suggested isoflurane increases
tau phosphorylation (Planel et al., 2004), more recent reports suggest that when anesthesiainduced hypothermia is controlled for, isoflurane does not increase tau phosphorylation (Tan et
al., 2010). To ensure our mice did not become hypothermic while under anesthesia, body
temperature was maintained at 37°C with a water pad connected to a recirculating water bath
(Gaymar Industries Inc., Orchard Park, NY).
A craniotomy was performed to allow access to the hippocampus. The reference
electrode was placed under the skin with a saline-soaked gauze pad in the hemisphere opposite
from the recording sites. The MEA/micropipette targeted the DG, CA3, and CA1 of the
hippocampus, all subregions known to be rich in glutamate receptors (Nimchinsky et al., 2004;
Pettit & Augustine, 2000). Stereotaxic coordinates for the different subregions of the
hippocampus were calculated using the mouse brain atlas (Paxinos & Watson 2004) [DG (AP: 2.3 mm, ML: +/-1.5 mm, DV: 2.1 mm), CA3 (AP: -2.3 mm, ML: +/-2.7 mm, DV: 2.25 mm),
CA1 (AP: -2.3 mm, ML: +/-1.7 mm, DV: 1.4 mm)] and confirmed in practice mice prior to
MEA testing. All MEA recordings were performed at 10 Hz using constant potential
amperometry. After the MEA reached a stable baseline (10-20 min), tonic glutamate levels (μM)
were calculated averaging extracellular glutamate levels over 10 seconds prior to any application
of solutions. In all three subregions of one hemisphere, evoked release was measured by local
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application of KCl delivered every 2-3 minutes. After 10 reproducible signals, the results were
averaged for each group.

Each signal was analyzed using (1) amplitude (μM), maximum

glutamate release, (2) Trise, time for the signal to reach maximum amplitude, (3) T 80 (sec), time
for the signal to decay 80% from the peak amplitude, and (4) uptake k-1 (sec-1), the slope of
linear regression of the natural log transformation of the decay over time (Figure 5) (Hinzman et
al., 2010; Hinzman et al., 2012; Nickell, Salvatore, Pomerleau, Apparsundaram, & Gerhardt,
2007). KCl-evoked release of glutamate was measured to determine the capacity or “ceiling” of
the terminal to release glutamate (Hinzman et al., 2010).
To control for differences in extracellular glutamate levels, thereby allowing a clean
interpretation of clearance parameters, exogenous glutamate was applied in the opposite
hemisphere. After the MEA reached a stable baseline (10-20 min), varying volumes of 200 μM
sterile-filtered glutamate solution were applied into the extracellular space every 2-3 minutes.
Glutamate signals with amplitudes in the 0 – 40 μM range were analyzed as this was the
physiological range of KCl-evoked glutamate release observed in the current study. Amplitudes
were matched across the groups and glutamate clearance (T80 and k-1) was measured.The
hemispheres used for KCl and glutamate application were counterbalanced as was the order of
subregions within a hemisphere.
Statistical analyses. All statistical analyses were performed using Systat11 (Systat
Software, Inc., Chicago 60606). Statistical analysis consisted of ANOVA and repeated-measures
ANOVA (RMANOVA). The Type I error rate (So was set at .05 for all omnibus tests and
Bonferroni post hoc comparisons. For the RMANOVA of behavioral data, transgene status
served as the between-subject variable, and session served as the within-subject variable.
Amperometric data were analyzed using a custom Microsoft excel software program (MatLab) to
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determine the tonic levels and KCl-evoked signal parameters. To determine concentrations of
glutamate in the hippocampus, the background current from the sentinel sites was subtracted
from the signal obtained from the GluOx recording sites. The resting current (pA) was divided
by the slope (μM/pA) obtained during calibration and reported as a concentration of tonic
glutamate. Using Pearson r correlations, we correlated KCl-evoked release in the CA3 with
errors made during the 24-hour probe trial of the Barnes maze.
Results
Barnes maze: spatial learning and memory. TauP301L mice made more errors across
acquisition training days (days 3-7) than the Controls [Tg main effect: F(2,25) = 4.32, p = .03]
(Figure 5B); errors between the groups did not differ across acquisition [Tg*Day interaction:
F(8,100) = 1.64, p = .12]. Latency did not differ among the groups during acquisition [Tg main
effect: F(2,25) = 1.45, p = .25; Tg*Day interaction: F(8,100) = 1.39, p = .21]. For the 24 hour
probe trial, TauP301L mice more errors than Controls and TauWT mice, with a marginal effect
[F(2,23) = 3.13, p = .06)] (Figure 5C). To determine whether mice extinguished preference for
the target hole where the escape box had been located across the 90 sec probe trial (Devan et al.,
2003), probe trial errors were binned into three 30 sec epochs. TauP301L mice made
significantly more errors than Controls and TauWT mice in the middle, 30-60 sec epoch [F(2,23)
= 3.98, p = .03)] (Figure 5D). For the 1 week probe trial, there were no differences among the
groups for total errors, errors in the three epochs, or latency (p > .05).
In vivo microelectrode recordings: tonic and evoked glutamate release. Tonic
glutamate levels were not significantly different in the DG [F(2,17) = .15; p = .86], CA3 [F(2,16)
= .11; p = .89], or CA1 [F(2,17) = .58; p = .57] among the Controls, TauWT, or TauP301L mice
(Figure 7A). Local application of 50-100 nL of 70 mM KCl produced reproducible glutamate
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release in all regions of the hippocampus. Though resting levels did not differ among the groups,
KCl-evoked glutamate release was significantly increased in TauP301L mice (Figure 7B). The
amplitudes of KCL-evoked-glutamate release in the dentate gyrus and CA1 were similar among
the groups, whereas in the CA3, the amplitude of KCl-evoked glutamate release was 7 times
larger in the TauP301L mice [Tg main effect; F(2,17) = 4.33, p = .03]. Also, a significantly
longer T80, time for the signal to decay by 80% from the peak amplitude, was observed following
KCl-evoked glutamate release in DG of TauP301L mice [F(2,18) = 3.68, p = .04; Table 1].
Clearance parameters (T80 and K-1) were equivalent for all hippocampal regions across the
groups (Table 1).
KCl-evoked glutamate release in the CA3 was positively correlated with total probe
errors [r(19) = .501, p = .03] and probe errors in the first and last 30 s epochs [0-30 s: r(19) =
.479 p = .04; 60-90 s: r(19) = .452, p = .05, when all mice were included (Figure 8). When
examined by group (Table 2), the correlation was not statistically significant for TauWT or
TauP301L, but was surprisingly strong for Controls with r values reaching as high as 0.942.
In vivo microelectrode recordings: clearance parameters. Rapid application of
glutamate into the extracellular space allowed us to mimic endogenous glutamate release and
examine glutamate clearance back to baseline in vivo. Since the amplitude of glutamate signals
were similar among Controls, TauWT, and TauP301L mice in the DG [F(2,12) = .76; p = .49],
CA3 [F(2,13) = .52; p = .60], and CA1 [F(2,15) = .09; p = .91], we compared specific
parameters of glutamate clearance (Figure 9A). We calculated Trise, the time for signal to reach
maximum amplitude, to examine if transgene altered diffusion of glutamate in the extracellular
space. Because Trise was not significantly different among the groups DG [F(2,15) = 2.25; p =
.15], CA3 [F(2,13) = .51; p = .61], and CA1 [F(2,15) =.31; p = .74], any reductions in glutamate
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clearance were not due to diffusion from the point source (micropipette) to the MEA (Sykova,
Mazel, & Simonova, 1998)(Figure 9B). T80, time for the signal to decay to 80% from peak
amplitude, in the DG [F(2,12) = .33; p = .73], CA3 [F(2,13) = 1.16; p = .34], and CA1 [F(2,15)
= .24; p = .79] and K-1, a measure of glutamate uptake, in the DG [F(2,12) = .35; p = .71], CA3
[F(2,13) = .33; p = .73], and CA1 [F(2,15) =2.37; p = .13] were not significantly different among
Controls, TauWT, or TauP301L mice (Figure 9C-9D).
Discussion
We examined the extent of glutamate dysregulation in a TauP301L mouse model of AD
known to exhibit electrophysiological hyperexcitability prior to tangle deposition or neuronal
death (Crimins et al., 2012). The present study was the first to use in vivo amperometry to
examine glutamate dysregulation in the DG, CA3, and CA1 subregions of the hippocampus in an
AD mouse model. The hippocampal-dependent Barnes maze task was used to relate pathological
glutamate changes with functional deficits. TauP301L mice exhibited memory deficits with
greater total errors across acquisition days and probe trial errors. Though tonic glutamate levels
were unaltered in all three regions of the hippocampus, KCl-evoked glutamate release in the
CA3 was significantly increased in TauP301L mice. Glutamate clearance and uptake did not
differ among the groups.
The Barnes maze is a spatial memory task that requires animals to use spatial cues around
the room to learn the position of a hole that can be used to escape the brightly lit, aversive, open
surface of the maze. Rodents with hippocampal damage show impaired performance in the
Barnes maze, suggesting this is a hippocampal-dependent task (Fox, Fan, LeVasseur, & Faden,
1998; Pompl, Mullan, Bjugstad, & Arendash, 1999). Unlike the commonly used hippocampaldependent Morris water maze, the Barnes maze task does not require the mice to swim and is
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therefore considered less anxiogenic (Harrison, Hosseini, & McDonald, 2009), a notion
supported by findings of lower plasma corticosterone in rodents examined after the Barnes maze
compared to the Morris water maze task (Harrison et al., 2009). Because stress is related to both
an increase in extracellular glutamate (Popoli et al., 2012) and an increase in tau
hyperphosphorylation (Popoli et al., 2012; Sotiropoulos et al., 2011), the Barnes maze task was
identified as a more suitable measurement of memory for the current study. The present findings
confirm that the Barnes maze is a sensitive task for use with TauP301L mice, capable of
detecting subtle differences after a short duration of tau expression.
The tonic glutamate levels observed in the current study (1-3 uM) were similar to the
levels previously reported in the hippocampus of microdialysis studies using rats (1-4 uM)
(Herman & Jahr, 2007; Lerma, Herranz, Herreras, Abraira, & Martin del Rio, 1986; Miele,
Berners, Boutelle, Kusakabe, & Fillenz, 1996). Interestingly, in vitro studies using hippocampal
brain slices suggest much lower ambient glutamate concentrations, with values closer to 0.025
μM (Herman & Jahr, 2007). The reason for these discrepancies between in vitro and in vivo
studies is unclear and warrants further investigation.
P301L tau expression did not alter tonic glutamate levels. The lack of differences in tonic
glutamate for TauP301L mice is somewhat surprising given the increased VGLUT expression
and KCl-evoked release observed in these mice. However, in vitro studies using hippocampal
slices suggest tonic glutamate levels are not dependent on, or altered by, vesicular release but
may instead be due to differences in glia-dependent release of glutamate (Cavelier & Attwell,
2005; Jabaudon et al., 1999; Le Meur, Galante, Angulo, & Audinat, 2007). In vivo studies using
MEAs provide indirect support for this idea. In mice with traumatic brain injury, striatal tonic
levels were increased, yet KCl-evoked released remained unchanged (Hinzman et al., 2010).
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MEA research with aging rats shows that the opposite is also possible; aged rats exhibited
increased KCl-evoked release, but unaltered levels of tonic glutamate (Stephens, Quintero,
Pomerleau, Huettl, & Gerhardt, 2011), similar to the present findings. Future studies are needed
to further delineate and confirm glia as primary sources of tonic extracellular glutamate.
TauP301L mice exhibit increases in KCL-evoked glutamate release in all regions of the
hippocampus, but this increase was only significant in the CA3 region. The increased release of
CA3 glutamate in TauP301L suggests that the CA3 hyperactivity observed in MCI patients
performing memory tasks (Bakker et al., 2012) could be due to an increase in glutamate release,
though further work is needed to confirm this hypothesis. We also observed that evoked release
in the CA3 was positively correlated with errors in the BM task during the 24 hour probe trial,
suggesting that memory may be mediated in part by increases in glutamate release. Human
evidence also supports this view; in memory-impaired aged humans, poorer memory
performance correlates with CA3 hyperexcitability (Bragin et al., 1995). This relation is more
than correlation; reductions in CA3 activity improve memory in aged rats (Koh et al., 2010) and
MCI patients (Bakker et al., 2012). Similarly, increased hippocampal activation in MCI is
predictive of the degree and rate of cognitive decline, as well as the conversion to AD
(Mackenzie & Miller, 1994).
Recent work sheds light on one possible way in which hyperactivity might be permissive
for the development of AD. In AD, tau - typically an intracellular protein - is released into the
extracellular space and endocytosed by neighboring neurons (Liu et al., 2012). This spread
occurs along synaptically connected circuits, resulting in a prion-like cell-to-cell transmission of
tau pathology. Relevant to the current paper is the finding that presynaptic glutamate release is
sufficient to drive tau release into the extracellular space (Yamada et al., 2014). Thus, glutamate-
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mediated exocytosis of tau may indicate one mechanism for the trans-synaptic spread of tau
pathology associated with synaptic activity. This could also result in a vicious feed-forward cycle
whereby tau pathology increases glutamate release, which then propagates the spread of tau
pathology. Further studies are needed to establish the relevance of increased CA3 glutamate
release to the spread of tau pathology.
The increased KCl-evoked release observed in TauP301L mice could arise through
several different mechanisms. For example, the increased expression of VGLUT observed in
TauP301L mice could explain the increase in glutamate release. The number of VGLUT
molecules has a direct impact on the number of glutamate molecules released by a single
synaptic vesicle during exocytosis (Herzog, Takamori, Jahn, Brose, & Wojcik, 2006; N. R.
Wilson et al., 2005) and overexpression of VGLUT results in increased glutamate release,
leading to excitotoxic neurodegeneration and a shortened lifespan (Daniels et al., 2011). The
increase in KCl-evoked release could also be explained by a reduction in glutamate transporter
expression, resulting in slower clearance of evoked glutamate from the synapse. That is, it is
possible increased levels observed after local application of KCl are not due to increased release
but rather less clearance, leading to overall higher levels. However, when exogenous glutamate
was applied, no differences in clearance were observed in TauP301L mice.
In many neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS)
(Rothstein, Van Kammen, Levey, Martin, & Kuncl, 1995), Huntington’s disease (Arzberger,
Krampfl, Leimgruber, & Weindl, 1997), Parkinson’s disease (Ferrarese et al., 1999), and
Alzheimer’s disease (Masliah et al., 2000), astrocytic glutamate transporter expression is
decreased. However, because brains are often examined at the end-stage of these diseases,
neuronal loss is often extensive, making it difficult to discern the role of glutamate transporters
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in the pathogenesis of these diseases. To better examine the role of glutamate transporters in the
etiology of AD, mouse models have been examined. In JNPL-c tau transgenic mice, which also
express the P301L mutation in tau but throughout the brain, glutamate transporter (GLT-1)
expression is increased by about 25% (Liao et al., 2009). Interestingly, this increase in GLT-1
expression is associated with decreased damage following stroke-induced excitotoxicity (Liao et
al., 2009). Whether the increase in GLT-1 expression associated with P301L tau is a
neuroprotective or compensatory response for increased glutamate release is unclear. Evidence
that increase in GLT-1 expression might be a compensatory response for alterations in glutamate
release comes from MEA studies examining aged rats. In the DG of older rats, glutamate uptake
is increased (Stephens et al., 2011). This age-associated increase in glutamate uptake coincides
with an increase in glutamate release, suggesting a possible compensatory response.
There is also evidence for a compensatory increase in glutamate transporters in human
brain tissue. Compared to age-matched controls, examination of post-mortem AD brain tissue
showed increased EAAT1 expression in neurons, as opposed to astrocytes, the more typical
location of EAAT1 (Scott et al., 2002). Tau was colocalized to the same pyramidal neurons that
expressed EAAT1, suggesting that neuronal transporter changes may also be related to tau
pathology. Similarly, EAAT2, typically found on astrocytes in healthy tissue, are also found in
neurons in AD post-mortem brain tissue (Thai, 2002). It is tempting to propose that neuronal
expression of EAAT1 and EAAT2 represents a neuroprotective response to combat
excitotoxicity. It will be important that future studies measure transporter expression in
concordance with the microelectrode studies and distinguish between neuronal versus astrocytic
transporter expression.
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One potential caveat of the current study concerns the high spatial resolution of the
microelectrodes. Because of the high spatial resolution, it is possible that different coordinates
within the various subregions of the hippocampus would result in different effects than those
observed here. In fact, when examined using MEAs, tonic glutamate levels were increased in rat
with traumatic brain injury but only at certain depths within the striatum (Hinzman et al., 2010);
increases in tonic glutamate levels were observed at a depth of 4.0 mm, but not at 4.5 mm or 5.0
mm. Thus, examination of TauP301L mice using slightly different coordinates might reveal
different results. Though the spatial resolution can be a limitation, it is also a benefit, allowing
subregional analyses and measurements of fast transmission close to the synapse.
In conclusion we used MEAs in combination with TauP301L mice to examine the effects
of P301L tau expression on glutamate signaling, without other mediators, such as Aβ plaques,
tangles, and neuronal loss. Our results demonstrate memory-impaired TauP301L mice exhibit a
7-fold increase in KCL-evoked glutamate release in the CA3 region of the hippocampus. The
more research is needed to determine the specific mechanisms responsible for elevations in
glutamate release and the potential implications for the spread of tau pathology.
Limitations. Although mice were anesthetized, and anesthesia often alters resting
glutamate levels (Mattinson et al., 2011) and tau phosphorylation (Planel et al., 2004), mice were
anesthetized with isoflurane, which does not alter glutamate levels or tau (Tan et al., 2010). A
second potential caveat of the current study concerns the high spatial resolution of the
microelectrodes. Because of the high spatial resolution, it is possible that different coordinates
within the various subregions of the hippocampus would result in different effects than those
observed here. Thus, examination of TauP301L mice using slightly different coordinates might
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It should also be noted that although we examined glutamate

dysregulation, we did not directly measure hyperexcitability using electrophysiology.
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Table 1
Clearance Parameters of KCl-Evoked Glutamate Release

K-1 (sec-1)

T80 (sec)
Controls

TauWT

TauP301L

Controls

TauWT

DG

1.74± .54

2.19± .61

8.56± 3.34*

2.69± 1.73 1.67± 1.01

2.83± 1.31

CA3

3.77± 1.23

4.01± .77

5.13± 1.53

4.61± 1.96 .64± 1.13

2.82± 1.75

CA1

2.27± .69

4.83± 2.41

3.71± 1.03

3.36± .57

2.10± 1.36

1.02± .73

TauP301L

Mean ± SEM; DG n =7 ; CA3 n =7 ; CA1 n =7. *p< .05, ANOVA, Control vs. TauP301L.
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Table 2. Correlations between KCl-evoked glutamate release in the CA3 and errors in the 24
hour probe trial of the Barnes maze.
Controls

TauWT

TauP301L

Total
Probe
Errors

27.65 + 16.95 * KCl-Glut

93.66 + .63 * KCl-Glut

96.67 + .73 * KCl-Glut

r(6) = .909, p = .012

r(7) = .153, p = .744

r(6) = .55, p = .257

Epoch 1:
0-30 s

6.31 + 5.97 * KCl-Glut

27.28 + .37 * KCl-Glut

23.95 + .387 * KCl-Glut

r(6) = .942, p = .006

r(7) = .231, p = .618

r(6) = .527, p = .283

Epoch 2:
30-60 s

8.34 + 6.08 * KCl-Glut

39.22 – .56 * KCl-Glut

8.38.41 + .19 * KCl-Glut

r(6) = .929, p = .007

r(7) = .319, p = .486

r(6) = .365, p = .483

Epoch 3:
60-90 s

13.01 + 4.89 * KCl-Glut

27.15 + .82 * KCl-Glut

34.30 + .16 * KCl-Glut

r(6) = .755, p = .083
r(7) = .476, p = .279
r(6) = .431, p = .394
KCl-evoked glutamate levels in the CA3 were positively correlated with total errors in the 24
hour probe trial, epoch1, and epoch 2 in control mice, but were not significant in TauWT or
TauP301L. (p < .05, n= 6-7); potassium chloride (KCl), glutamate (Glut).
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Figure 1.TauP301L mice (+) exhibit a 65% increase in VGLUT1 expression in the hippocampus
and a 20% increase in the prefrontal cortex (PFC) compared to controls (-). Synaptophysin, a
marker of presynaptic terminals, and PSD95, a postsynaptic marker, did not differ between the
groups, indicating TauP301L mice do not exhibit synapse loss at the time point examined.
VGAT, the vesicular transporter for GABA, an inhibitory neurotransmitter, was decreased by
70% in the hippocampus and 40% in the PFC. Increased VGLUT and decreased VGAT are
predicted to produce excitotoxicity. Means ± SEM. (n = 12 per group). *p < 0.01. Vesciular
glutamate transporter 1 (VGLUT1); vesicular GABA transporter (VGAT); Post synaptic density
protein 95 (PSD95); α-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor 1
(GluR1); Glutamic acid decarboxylase 67 (GAD67); Synaptophysin (Synaptop.) (Data not
published).
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Figure 2. The trisynaptic circuit of the hippocampus. Information enters this unidirectional loop
through layer II of the entorhinal cortex (EC). The EC transmits signals along the perforant
pathway via axons and connects to the dentate gyrus (DG). The mossy fibres of the DG then
synapse onto pyramidal cells in the CA3, which connect to the CA1 region via the Schaffer
collaterals. From the CA1, projections lead to the subiculum (SC), where the SC, and to a lesser
extent the CA1, project to the EC again, forming the third link of the circuit. In addition, to the
unidirectional flow, layer III of the EC directly connects to the CA1 and SC (dotted lines), and
layer II of the EC provides direct connections to the CA3 via the perforant pathway. CA3
neurons also receive more than 95% of their input from recurrent CA3 collaterals, referred to as
“auto-associative” tracts.

GLUTAMATE DYSREGULATION IN A TAUP301L MOUSE MODEL

42

Figure 3. Suppression of tau. Using an antibody that recognizes human tau (Tau-13), the ability
of doxycycline (DOX) to suppress tau expression. DOX treatment in TauP301L mice (3M DOX
+/+) suppresses tau expression. Six month old mice on DOX from 0-3 months but allowed to
express tau from 3-6 months (6M (0-3M DOX)) express tau at approximately equal levels as
TauP301L mice expressing tau for 3 and 6 months without DOX treatment (3M +/+ and 6M
+/+). Tau negative mice, -/-; TauP301L mice, +/+.
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Figure 4. Microelectrode graphics. (A) Schematic drawing showing the configuration and
coatings applied to the MEA. The lower pair of platinum sites were prepared with a mixture of
glutamate-oxidase (GluOX), bovine serum albumin (BSA), and glutaraldehyde (Glut), illustrated
at left. The upper pair of platinum sites were prepared only with BSA and Glut, illustrated at
right. A layer of m-phenylenediamine (mPD) is electroplated onto the recording sites providing a
size exclusion layer to block major interferents, ascorbic acid (AA) and dopamine (DA). (B)
MEA in vitro calibration measuring the change in the GluOx site (blue line) and sentinel site (red
line) using multiple additions of glutamate (Glu). Addition of interferents (AA and DA)
produced no changes in concentration on the GluOx or sentinel sites. Three additions of
glutamate produced changes in concentration on the GluOx sites only while H 202 produced
changes on both the GluOx and sentinel sites.
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Figure 5. Illustrative in vivo recording from the GluOX sites (solid line) and sentinel sites
(dashed line). To measure resting (tonic) glutamate, current from the sentinel sites were
subtracted from the glutamate oxidase (GluOX) sites. Potassium chloride (KCl) was used to
examine the maximum amplitude of evoked glutamate release. Exogenous glutamate was applied
to measure clearance of glutamate from the synapse. T80, the time for the peak to decay to 80%
and k-1, the clearance rate, were used as clearance parameters.
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Figure 6. TauP301L mice exhibit memory deficits in the Barnes maze task. (A) Bodyweights
were not significantly different. (B) Errors during acquisition were significantly increased for
TauP301L mice. (C) TauP301L mice exhibited more errors during probe trials. (D) TauP301L
mice made more errors during the 30-60 sec epoch. (Mean ± SEM; *p<.05 Control vs.
TauP301L, ** p< .01 Control vs. TauP301L, # p< .05 TauWT vs. TauP301L, n = 7-11).
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Figure 7. Tonic and potassium chloride (KCl)-evoked release of glutamate in the DG, CA3, and
CA1 regions of the hippocampus. (A) Tonic glutamate levels were not significantly different in
the hippocampus. (B) The average amplitudes of KCl-evoked glutamate release in the CA3
region of hippocampus were significantly increased in the TauP301L mice after local application
of 50-100 nL of 70 mM KCl, compared to Controls or TauWT animals (Mean ± SEM; *p< .05
Control vs. TauP301L, n = 6-7).
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Figure 8. Correlations of CA3 KCl-evoked glutamate release. KCl-evoked glutamate release in
the CA3 was positively correlated with (A) total errors in the 24 hour probe trial, (B) Epoch 1: 030 s, (C) Epoch 2: 30-60 s, and (D) Epoch 3: 60-90 s. Potassium chloride, KCl; glutamate, Glu.
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Figure 9. Clearance parameters in the DG, CA3, and, CA1 using exogenous glutamate. (A)
When glutamate was applied, the amplitude of glutamate signal was similar among groups in
each region. (B) Trise, indicator of diffusion, was similar among groups in each region. (C) K-1,
indicator of glutamate uptake, did not differ among groups in each region. (D) T80, indicator or
glutamate clearance, did not differ among groups in each region.
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